ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1356

Increasing Oral Doses of GLPG1972 Administered Daily for 29 Days Show a Strong Target Engagement in Patients with Knee and/or Hip OA

Henri Deckx1, Simon Hatch2, Martine Robberechts1, Sonia Dupont3, Julie Desrivot3, Hugh Coleman4, Staffan Larsson5, André Struglics5, Ellen van der Aar1 and Ann Fieuw1, 1Galapagos NV, Mechelen, Belgium, 2Galapagos NV, Boston, MA, 3Galapagos SASU, Romainville, France, 4CRU, Covance, Daytona Beach, FL, 5Clinical Sciences, Lund University, Lund, Sweden

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Biomarkers, cartilage and osteoarthritis, DMOAD

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Osteoarthritis – Clinical Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Osteoarthritis (OA) is characterized by structural changes of the joint, of which degradation of articular cartilage is one of the major signs1. The main proteoglycan component of the extracellular matrix of articular cartilage is aggrecan. GLPG1972 as a potent and selective inhibitor of ADAMTS-5, a key aggrecan-cleaving enzyme involved in cartilage degradation, is being developed as a potential disease-modifying OA drug (DMOAD). Aggrecan cleavage by ADAMTS-5 results in release of N-terminal ARGS neoepitope fragments of which serum levels significantly decreased in healthy subjects treated with GLPG1972 during 14 days in a previous study².

The objective was to assess safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD, i.e. serum ARGS-aggrecan levels) during and following administration of GLPG1972 in patients with knee and/or hip OA.

Methods: this was a single center, randomized, double-blind, placebo-controlled, age and gender stratified, ascending dose Phase Ib study, with three semi-sequential cohorts of 10 patients each, randomized to GLPG1972 or placebo in a 4:1 ratio. Doses tested were once daily 100, 200 or 300 mg given orally. Treatment duration was 29 days. Patients had follow-up visits 14 and 21 days after last dosing for additional PD assessments. Methods for PD have been described previously³.

Results:

thirty patients were included. Of these, 24 patients (M/F rate 8/16, 14 aged 50-64 and 10 aged 65-75) received GLPG1972. All adverse events (AE) were mild and transient. No serious AEs were reported during the study; one female patient in the 300-mg group was discontinued after 15 days of treatment due to drug-related elevated transaminase values which returned to normal 9 days after treatment discontinuation while her bilirubin levels remained normal. There were no overall trends in lab abnormalities over time or significant changes in vital signs, ECG and Holter parameters. Steady state in plasma exposure was reached after 3-5 days of dosing. Exposure increased dose-proportionally. Mean serum ARGS levels (SEM) decreased steadily over time in all patients receiving GLPG1972: -40% (2.9), -46% (4.5) and -53% (2.8) at day 15 compared to baseline in the 100, 200 and 300 mg group respectively. These levels remained stable until last dose on day 29, then consistently returned to pre-dose levels for all groups 14 and 21 days after last dose. Placebo group levels remained unchanged.

Conclusion:

when administered daily for 29 days in patients with knee and/or hip OA, GLPG1972 at oral doses of 100, 200 and 300 mg q.d. was generally well tolerated and safe. Serum ARGS levels, as a marker for target engagement and potential proxy of cartilage degradation, showed a decrease over time up to 53% below baseline in the 300 mg group. These findings are consistent with what we observed in a previous study in healthy subjects² and reinforce the rationale for developing GLPG1972 as a DMOAD.

References:

  1. Hunter, D. J., et al. Curr. Opin. Rheumatol. 2009, 21, 110–117
  2. van der Aar E, et al. Arthritis Rheumatol. 2017; 69 (suppl 10)
  3. Larsson et al. Osteoarthritis Cartilage 2014, 22(2):242-9

Disclosure: H. Deckx, Galapagos N.V., 1, 3; S. Hatch, Galapagos NV, 3, 5; M. Robberechts, Galapagos NV, 3; S. Dupont, Galapagos NV, 3; J. Desrivot, Galapagos NV, 3; H. Coleman, None; S. Larsson, None; A. Struglics, None; E. van der Aar, Galapagos N.V., 1, 3; A. Fieuw, Gelapagos NV, 3.

To cite this abstract in AMA style:

Deckx H, Hatch S, Robberechts M, Dupont S, Desrivot J, Coleman H, Larsson S, Struglics A, van der Aar E, Fieuw A. Increasing Oral Doses of GLPG1972 Administered Daily for 29 Days Show a Strong Target Engagement in Patients with Knee and/or Hip OA [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/increasing-oral-doses-of-glpg1972-administered-daily-for-29-days-show-a-strong-target-engagement-in-patients-with-knee-and-or-hip-oa/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/increasing-oral-doses-of-glpg1972-administered-daily-for-29-days-show-a-strong-target-engagement-in-patients-with-knee-and-or-hip-oa/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology